Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium + olodaterol versus tiotropium for breathlessness during 3-minute CSST in COPD
NL-OMON42990Phase 4Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Intensity of breathlessness during the 3-minute Constant Speed Shuttle Test. Started Oct 2016; status: active, not recruiting.
02
Drugs
tiotropiumolodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON42990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42990.